Small Molecule AMPK Activators via Fbxo48 Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that prevent the ubiquitination and subsequent degradation of AMP-activated protein kinase (AMPK), as improper activation of AMPK due to disrupted feedforward loops leads to metabolic defects and is implicated in conditions like cancer and metabolic disorders.
Innovation Solution
Development of specific compounds, such as those represented by Formulas I and II, which bind to ubiquitin E3 ligases like Fbxo48, thereby preventing the interaction and degradation of phosphorylated-AMPK, thereby stabilizing and activating AMPK.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ubiquitin E3 ligase (Fbxo48) interacts with AMPK, then AMPK degradation occurs and cellular energy homeostasis is disrupted, but preventing this interaction requires developing specific small molecule compounds
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to ubiquitin E3 ligase Fbxo48, preventing its interaction with AMPK. These compounds act as mediators between the ligase and substrate, blocking the degradation pathway while maintaining cellular homeostasis. The compounds include specific structural features (Formula I and II) that enable selective binding to Fbxo48 without activating it.
Solution Approach 2:
The patent modifies chemical parameters of small molecules to optimize their binding affinity to Fbxo48 while maintaining selectivity. By adjusting molecular weight, hydrophobicity, and specific functional group positions in Formulas I and II, the compounds achieve optimal inhibition of the Fbxo48-AMPK interaction without off-target effects.
2Reliability
If AMPK activation is increased to treat metabolic disorders, then therapeutic benefit is improved, but improper activation can lead to adverse effects
Solution Approach 1:
Instead of directly activating AMPK (which could cause improper activation), the patent inverts the approach by inhibiting Fbxo48-mediated degradation. This indirect activation method allows AMPK levels to increase naturally through reduced degradation, avoiding the risks of direct activation while achieving therapeutic benefits for metabolic disorders.
Solution Approach 2:
The compounds enable feedback-controlled AMPK activation by blocking the degradation pathway. As AMPK levels increase, the feedback loop naturally regulates activation levels, preventing overactivation and associated adverse effects. This creates a self-regulating system that responds to cellular energy status.
Data Source
Figure 1A~1D
Figure 2A~2B
Figure 3A~3C
AI summary
Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.